PDCD1 and neoplasm: Research suggests that the efficacy of PD-1 inhibitors in GC patients is associated with PD-L1 expression levels.[20] Tumor cells, tumor-associated immune cells, and stromal cells often express the ligand PD-L1 to evade immune attack.